Disclosures

Josep O. Dalmau, MD, PhD

Editorial Boards:

Editor of Neurology: Neuroimmunology & Neuroinflammation 
Annals Neurology

Patents:

       Patent for Ma2 autoantibody test: US 6,387,639; Issued May 14th, 2002. Patent for NMDA receptor autoantibody test: US 7,972,796 B2 July 5, 2011; European 2057466. Patent for GABAb receptor                 autoantibody test: US 8,685,656; European 2483417; Patents filed for GABA(A) receptor autoantibody test, DPPX autoantibody test, and IgLON5 autoantibody test.

Publishing Royalties:

Neurology- UpToDate, Wolters Kluwer contributing author, receive royalties Medlink Neurology contributing author, receive royalties

Consultancies:

Advance Medical

Research Support, Commercial Entities:

Research support (allosteric modulation of NMDAR) from SAGE Therapeutics

Research Support, Government Entities:

Instituto Carlos III/FEDER (FIS, 17/00234, CIBERER CB15/00010, Proyectos Integrados de Excelencia, PIE 16/00014 and AC18/00009). -Agencia de Gestio d'Ajuts Universitaris i de Recerca (AGAUR), and CERCA Programme Generalitat de Catalunya

Research Support, Foundations and Societies:

Safra Foundation Sage therapeutics Cellex Foundation La Caixa Health Foundation

Royalty Payments, Technology or Inventions:

Ma2 autoantibody test (tech/invention), Athena Diagostics via Memoral Sloan Kettering, current NMDA receptor, GABA(B) receptor autoantibody tests (tech/invention), Euroimmun, Inc via University of Pennsylvania, current GABA(A) receptor, DPPX and IgLON5 autoantibody tests (tech/invention), Euroimmun, Inc via Institucio Catalana de Recerca i Estudis Avancats (ICREA); Institut d'Investigacions Biomediques August Pi i Sunyer (IDIBAPS)